Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Double-blind, Randomized, Sham-controlled, Dose-response, Study Evaluating the Safety and Tolerability of TG-C in Subjects With Chronic Discogenic Lumbar Back Pain Due to Degenerative Disc Disease at 6 and 12 Months

NCT06144970 is registered in ClinicalTrials.gov with Kolon TissueGene, Inc. as lead sponsor.

NCT NCT06144970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06144970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Double-blind, Randomized, Sham-controlled, Dose-response, Study Evaluating the Safety and Tolerability of TG-C in Subjects With Chronic Discogenic Lumbar Back Pain Due to Degenerative Disc Disease at 6 and 12 Months
Lead sponsor
Kolon TissueGene, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 19, 2027
Completion date
July 28, 2029
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative disc disease